{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
Basel, 19 July 2007\line \line {\b Roche in the first half 
of 2007: Strong performance continues} \line {\pard\f0\li0\ri0\sa360\sl360\fs22 Download 
PDF: \u160?\u160?\u160?\u160?\u160?English (http://www.roche.com/mrhy07e.pdf) 
\u160?\u160?\u160?\u160?\u160?German (http://www.roche.com/mrhy07d.pdf) \u160?\u160?\u160?\u160?\u160?French (http://www.roche.com/mrhy07f.pdf) 
\u160?\u160?\u160?\u160?\u160?Spanish (http://www.roche.com/mrhy07sp.pdf)\line \line Half-Year 
Report 2007\line \line Presentation (http://www.roche.com/irphy07.pdf) (Investor Relations)\line \line \line {\b Group} \line \u8226? 
Group sales advance 15% to 23 billion Swiss francs, for an organic half-year increase of 3 billion Swiss 
francs\line \u8226? Operating profit margin rises 3.6 percentage points to 32.8%\line \u8226? 
Net income increases 29% in Swiss francs to 5.9 billion Swiss francs, thanks to outstanding operating 
results and a further increase in net financial income\line \u8226? Core Earnings per Share (EPS) 
up 21% to 5.95 Swiss francs, significantly outpacing sales growth\line \line {\b Pharmaceuticals} \line \u8226? 
Pharmaceutical sales increase 18%, almost three times the global market growth rate\line \u8226? 
Cancer medicines deliver 22% growth, expanding Roche\u8217?s market leadership in oncology\line \u8226? 
Operating profit margin rises 4.1 percentage points to 36.3%\line \u8226? Herceptin, Avastin and 
Xeloda approved for additional cancer indications in the EU and Japan\line \u8226? Three phase III 
studies with Actemra meet primary endpoints\line \u8226? New biotech manufacturing facilities opened\line \line {\b Diagnostics} \line \u8226? 
Sales up 5%, reinforcing the division\u8217?s global market leadership\line \u8226? Operating profit margin 
of 20.8%; EBITDA margin well above industry average\line \u8226? BioVeris Corporation and 454 Life 
Sciences acquisitions and proposed NimbleGen Systems, Inc. transaction will complement existing portfolio\line \u8226? 
Tender offer made for Ventana Medical Systems, Inc. for access to tissue-based diagnostic tests \line \line {\b Confirmed 
outlook for 2007 } \line \u8226? Double-digit sales growth for the Group and the Pharmaceuticals 
Division\line \u8226? Above-market sales growth in both divisions\line \u8226? The target is 
for Core EPS to grow above Group sales\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 Barring unforeseen 
events \u8211? unless otherwise stated, all growth rates are in local currencies.\par}\line  
\line Commenting on the Group\u8217?s performance in the first half of 2007, Roche Chairman and 
CEO Franz B. Humer said: \u8216?Roche posted impressive half year results, continuing the robust growth of 
previous years. Interim sales rose 15%, resulting in additional market share gains, particularly for 
the Pharmaceuticals Division. On top of this substantial organic sales increase we achieved another 
significant improvement in the Group\u8217?s profitability. Thanks to the very good performance by both divisions 
and a further improvement in net financial income, the Group\u8217?s net income reached 5.9 billion Swiss 
francs, an increase of 29%. At the same time we have positioned ourselves even more strongly for future 
growth through good progress in our R&D projects and a number of strategic acquisitions.\u8217?\line \line \line {\b Roche 
Group} \line \line {\b Continued strong demand for key products} \line \line {\b Key 
figures in millions of Swiss francs} \line 
		First halfFirst half        % change     % change    
	
		20072006in CHFin local cur.
	
		Sales22,827 19,849+15+15
	
		Research and development3,6353,063+19+21
	
		EBITDAa)8,7037,061+23+22
	
		Operating profit before exceptional items7,4775,805+29+27
	
		Net income5,8624,543+29-
	
		Core EPSb) (in CHF)5.954.90+21-
	
		Employees (in full-time equivalents)c)76,65574,372+3-
	\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 a) 
EBITDA: Earnings before financial income, financing costs, tax, depreciation and amortisation, including 
impairment. This corresponds to operating profit before depreciation and amortisation, including impairment.\line b) 
Core earnings per share and non-voting equity security (diluted) is calculated as shown on p. 48 of 
Roche\u8217?s 2007 Half-Year Report.\line c) Employees 2006 as per 31 December 2006\par}\line \line The 
Roche Group posted strong results for the first half of 2007. Group sales advanced 3 billion Swiss francs 
to 22.8 billion Swiss francs, for a growth rate of 15% in local currencies (15% in Swiss francs and 
19% in US dollars). The Pharmaceuticals Division was the main growth driver. Its sales increased 18% 
in local currencies (17% in Swiss francs), or almost three times the global market average. Growth was 
fuelled primarily by continued strong demand for key medicines in the division\u8217?s oncology, metabolism, 
transplantation and virology portfolios, including substantial sales of the anti-influenza medicine 
Tamiflu for pandemic preparedness. Lucentis, Genentech\u8217?s recently launched medicine for age-related 
blindness, was also a major contributor to growth. In the Diagnostics Division sales increased at an 
above-market rate of 5% in local currencies (7% in Swiss francs), with the main impetus coming from 
the division\u8217?s Professional Diagnostics and Diabetes Care units.\line \line {\b Operating 
profit margin clearly above 30%} \line Strong interim sales had a very positive impact 
on the Group\u8217?s profitability. Operating profit rose 27% in local currencies to 7.5 billion Swiss francs. 
The corresponding margin improved significantly, rising 3.6 percentage points to 32.8%, as strong sales 
growth in the Pharmaceuticals Division more than offset increased investment in launch and pre-launch 
activities and in Roche\u8217?s highly promising development pipelines. The Pharmaceuticals Division\u8217?s operating 
profit rose 31% in local currencies to 6.6 billion Swiss francs, increasing the division\u8217?s operating 
profit margin by 4.1 percentage points to 36.3%. \line \line Operating profit in 
the Diagnostics Division rose 3% in local currencies to 949 million Swiss francs. Although there was 
a margin decline of 0.5 percentage points to 20.8%, the cash generation of the business remains well 
above industry average with an EBITDA margin of 30.5%. The lower operating margin was primarily due 
to continued investments in product launches and also higher costs of sales due to changes in the product 
mix and costs of instrument placements.\line \line {\b Net income close 
to 6 billion Swiss francs} \line Net financial income totalled 500 million Swiss francs, 
an 18% increase over the first half of 2006. The Group\u8217?s effective tax rate for the period decreased 
to 26.5%. Net income increased substantially in the first six months, advancing 29% to 5.9 billion Swiss 
francs. The Group further strengthened its balance sheet. The ratio of equity to total assets is now 
66%, and 84% of total assets are financed long term.\line \line {\b Outlook} \line We 
reaffirm the raised outlook announced in April. For full-year 2007, we expect the Group\u8217?s and the Pharmaceuticals 
Division\u8217?s sales to grow at double-digit rates in local currencies. In both the Pharmaceuticals Division 
and the Diagnostics Division, we anticipate continued above-market sales growth. Our EPS target is for 
Core EPS to grow above Group sales.\line \line {\b Pharmaceuticals Division\line \line Sales 
growth at almost three times the global market rate} \line \line 
		Key figuresIn millions of CHF% change in CHF% change in local currenciesAs % of sales
	
		Sales 18,2681718100
	
		- Roche Pharmaceuticals11,367181662
	
		- Genentech5,227242829
	
		- Chugai1,674-179
	
		EBITDA7,424272640.6
	
		Operating profit6,640323136.3
	\line \line The 
Pharmaceuticals Division maintained strong growth in the first half of 2007, with sales rising 18% in 
local currencies (17% in Swiss francs) over the same period last year. This is almost three times the 
global market rate of 6.5%. Growth was driven primarily by strong demand for the division\u8217?s leading 
oncology medicines, other key products and Genentech\u8217?s medication Lucentis (for blindness), as well 
as continued pandemic stockpiling of the influenza medicine Tamiflu. Sales outpaced market growth more 
than threefold in North America (24% vs 7%) and well over twofold in Europe (16% vs 6%). In Japan sales 
returned to above-market growth. Chugai posted a sales increase of 7% for the first half-year, compared 
with a market growth rate of 1%, driven primarily by sales of Tamiflu for pandemic stockpiling, Herceptin 
and Evista (for osteoporosis).\line \line Divisional operating profit for the first 
half of 2007 amounted to 6.6 billion Swiss francs, a rise of 31% in local currencies compared with the 
year-earlier period. The corresponding margin increased by 4.1 percentage points to 36.3%. Sales grew 
significantly faster than marketing costs, which rose as a result of higher support costs, particularly 
for the oncology portfolio, and expenditure for launch and pre-launch activities, notably for Avastin 
and Tarceva. Research and development expenses advanced ahead of sales, with significant investments 
in our strong pipeline reflecting the expanded portfolio and large number of late-stage clinical trials. 
Divisional EBITDA totalled 7.4 billion Swiss francs, or 40.6% of sales, compared with 37.5% in the first 
six months of 2006.\line \line {\b Oncology \u8211? market leadership strengthened 
further} \line The division\u8217?s oncology portfolio delivered robust first-half sales growth 
of 22%. All major brands contributed to this performance, which further consolidates Roche\u8217?s position 
as the world\u8217?s leading provider of cancer medicines.\line \line Worldwide sales 
of MabThera/Rituxan (rituximab) for non-Hodgkin\u8217?s lymphoma (NHL) continued to rise strongly in the first 
half of 2007. Growth continues to be driven primarily by widespread use of the product in the first-line 
treatment of both indolent and aggressive NHL in Europe and the US. Particularly in Western Europe, 
sales are also being helped by growing adoption of MabThera as maintenance therapy for relapsed or refractory 
follicular lymphoma, the most common form of indolent NHL.\line \line Herceptin 
(trastuzumab), for early and advanced HER2-positive breast cancer, again recorded a strong global sales 
increase, driven primarily by data demonstrating the product\u8217?s survival benefit in early-stage disease. 
In April Roche received EU approval for Herceptin in combination with hormonal therapy (aromatase inhibitor) 
for the treatment of patients with advanced breast cancer that is both HER2-positive and hormone receptor-positive. 
This is the first combination of targeted therapies to be approved for the treatment of breast cancer. 
New data presented at the annual American Society for Clinical Oncology (ASCO) meeting in June show 
that giving Herceptin plus chemotherapy before surgery can eradicate breast tumours in nearly twice 
as many patients as chemotherapy alone.\line \line Avastin (bevacizumab), the first 
anti-angiogenic therapy to demonstrate survival benefits in advanced colorectal, breast, lung and kidney 
cancer, continues to record very strong sales growth in all regions. At the end of March Avastin gained 
approval in the EU as a first-line treatment for advanced breast cancer, the third major cancer type 
for which it has been licensed after colorectal cancer (EU, US and now Japan) and non-small cell lung 
cancer (US). In April, following priority review, the Japanese health authorities approved Avastin for 
advanced or recurrent colorectal cancer; Chugai began the market rollout in June. As planned, Roche 
filed an application with the European Medicines Agency (EMEA) in April to expand the product\u8217?s EU marketing 
approval in advanced colorectal cancer to include combinations with chemotherapy regimens based on oxaliplatin. 
Also in April Roche applied for EU marketing approval for Avastin in the first-line treatment of advanced 
renal cell carcinoma, the most common type of kidney cancer. The EMEA is also reviewing an application 
Roche filed last August for approval of the product in the treatment of non-small cell lung cancer (NSCLC), 
the most common form of the disease; we have now provided the agency with further data \u8212? from the AVAiL 
trial \u8212? complementing the original NSCLC filing.\line \line The results of two major 
phase III clinical trials with Avastin were presented at the ASCO meeting in June. The Avastin in Lung 
(AVAiL) study showed that adding Avastin to cisplatin/gemcitabine chemotherapy significantly improves 
the time patients with advanced NSCLC live without their disease progressing (progression-free survival) 
compared with chemotherapy alone. The Avastin in Renal Cell Cancer (AVOREN) study showed that adding 
Avastin to interferon therapy nearly doubled progression-free survival compared with interferon alone.\line \line Sales 
of the oral cancer medicine Xeloda (capecitabine) continue to advance strongly in all markets, driven 
by increasing use of the product after surgery in colon cancer patients and its use in the first-line 
treatment of advanced colorectal cancer and late-stage breast cancer. At the end of March Xeloda was 
approved in the EU for the treatment of stomach cancer, the second-largest cause of cancer deaths worldwide. 
Roche has now submitted regulatory applications in the US and the EU for approval of Xeloda in combination 
with oxaliplatin (with or without Avastin) for first-line treatment and in combination with oxaliplatin 
for second-line treatment of metastatic colorectal cancer.\line \line Global sales 
of Tarceva (erlotinib), the only human epidermal growth factor receptor (EGFR) inhibitor with a proven 
survival benefit in advanced NSCLC and pancreatic cancer, continued to grow strongly. Since its approval 
for advanced pancreatic cancer in November 2005 in the US and January this year in the EU, Tarceva continues 
to show solid market uptake in this indication as well. Chugai\u8217?s application for approval of Tarceva 
in advanced or recurrent NSCLC is undergoing priority review by the Japanese authorities.\line \line {\b Anemia 
\u8211? sales affected by price cuts } \line Combined sales of Roche\u8217?s NeoRecormon and Chugai\u8217?s 
Epogin (epoetin beta) declined overall in the first half-year. Sales of NeoRecormon decreased 2% in 
a highly competitive environment, and sales of Epogin in Japan were down 9% due to the continuing impact 
of government-mandated price cuts and reimbursement changes.\line \line {\b Transplantation 
\u8211? double-digit growth for CellCept} \line The immunosuppressant CellCept (mycophenolate 
mofetil), for the prevention of transplant rejection, maintained its sales growth worldwide and remains 
the top-selling branded immunosuppressant in the US.\line \line {\b Virology 
\u8211? government orders for pandemic preparedness} \line Continued growth in sales of the 
influenza medicine Tamiflu (oseltamivir) in the first half-year was driven by stockpiling orders, as 
governments and corporations prepare for a potential flu pandemic. The mild 2006/2007 flu season resulted 
in lower sales of the product for seasonal use. We have now received government orders for a total of 
some 215 million treatment courses from more than 80 countries worldwide. The global manufacturing network 
Roche has put in place over the last two years can produce 400 million treatment courses of Tamiflu 
annually, if required. As this significantly exceeds current demand, we are tailoring production levels 
accordingly, while retaining the ability to increase output rapidly, should the need arise. In February 
and March, respectively, Roche filed marketing applications in Europe and the US for a smaller, lower-strength 
capsule formulation of Tamiflu intended primarily for use in children. The new formulation was approved 
in the US at the beginning of July.\line \line Sales of Pegasys (peginterferon alfa-2a), 
for hepatitis B and C, in the first half of 2007 were boosted by continuing uptake in emerging markets, 
particularly Brazil and China. Following approval by the Japanese authorities of combined Pegasys and 
Copegus (ribavirin) for chronic hepatitis C in January, Chugai started the market rollout in March. 
In March Roche received EU approval for a change to the Pegasys prescribing information to allow a shorter, 
24-week treatment period in some patients infected with hepatitis C genotypes 1 or 4 who show a rapid 
response to therapy.\line \line The HIV medicine Fuzeon (enfuvirtide) posted a sales 
increase of 8% to 155 million francs, with growth in all regions where the product is sold.\line \line In 
June, in cooperation with national health authorities, Roche initiated a recall of all batches of Viracept 
(nelfinavir) in Europe and some other regions. Supplies of Viracept in the US, Canada and Japan are 
not affected, as Pfizer manufactures the product sold in these countries. The recall is due to the discovery 
of a chemical impurity in some production batches. The cause has been identified, and Roche has taken 
the necessary steps to prevent a recurrence. The product\u8217?s EU marketing licence has been suspended while 
further reviews and tests are performed. We are also cooperating with healthcare providers, patient 
groups and NGOs and will establish registries to enable follow-up of patients who may have been exposed 
to the impurity. Our goal is to safeguard patient welfare and restore supplies of Viracept as quickly 
as possible.\line \line Valcyte (valganciclovir) and Cymevene (ganciclovir), the 
world\u8217?s leading treatments for the prevention and treatment of cytomegalovirus disease in transplant 
patients and people with HIV/AIDS, continued the strong growth seen in 2006. Combined sales rose 17% 
to 261 million Swiss francs in the first half of 2007, with all markets contributing.\line \line {\b Autoimmune 
diseases \u8211? increasing adoption of MabThera in RA} \line We are seeing steady adoption 
of MabThera/Rituxan for rheumatoid arthritis (RA), as doctors gain experience in the treatment of RA 
patients with this novel antibody-based medicine. New data were recently added to the European prescribing 
information on the ability of MabThera to significantly slow progression of joint damage in patients 
who have not been helped by or are unable to tolerate treatment with tumour necrosis factor inhibitors. 
Phase III studies in patients with earlier-stage RA, one assessing the product\u8217?s efficacy in preventing 
structural damage and three others investigating its ability to improve disease signs and symptoms, 
are progressing as planned. The results of some of these trials are expected early in 2008.\line \line {\b Metabolic 
diseases \u8211? successful rollout of Bonviva/Boniva} \line Sales of Bonviva/Boniva (ibandronic 
acid), available as a once-monthly tablet and three-monthly injection for the treatment of postmenopausal 
osteoporosis, increased 127% to 374 million Swiss francs. Successful launches in France and Spain earlier 
this year helped further strengthen European sales. In the US Boniva has widened its share of the oral 
bisphosphonate market to over 13%.\line \line Sales of Roche\u8217?s prescription weight-loss 
medication Xenical (orlistat 120 mg) decreased 8% to 339 million Swiss francs in the first half-year. 
In February Roche and GlaxoSmithKline Consumer Healthcare signed an agreement giving GSK exclusive rights 
to market non-prescription formulations of orlistat globally, except in Japan. Under an existing agreement 
GSK already has the US marketing rights to non-prescription orlistat 60 mg, which it has launched under 
the brand name alli.\line \line {\b Research and development \u8211? all major 
projects on track} \line In the first six months of 2007 the Pharmaceuticals Division 
filed ten major marketing applications and gained seven major regulatory approvals (see table, p. 12). 
At the end of June the division\u8217?s R&D pipeline comprised 112 clinical projects, including 54 new 
molecular entities (NMEs) and 58 additional indications. Thirty NMEs are currently in phase I, 19 in 
phase II and three in phase III development; two have been filed for regulatory review. In the first 
half-year nine projects entered phase II and three entered phase III; three phase II projects were discontinued, 
one of which reverted to our partner. There were no discontinuations in phase III.\line \line Phase 
III testing of the HER2 dimerisation inhibitor pertuzumab (formerly also called Omnitarg) in patients 
with breast cancer is scheduled to start towards the end of 2007. The results of phase II clinical trials 
presented at the ASCO meeting in June show that the drug has substantial antitumour activity in patients 
with pretreated metastatic HER2-positive breast cancer when given with Herceptin.\line \line Mircera, 
Roche\u8217?s novel continuous erythropoietin receptor activator, has a unique mechanism of action that differentiates 
it from existing erythropoiesis-stimulating agents (ESAs). In May Roche received an approvable letter 
from the US Food and Drug Administration (FDA) for Mircera for the treatment of anemia associated with 
chronic renal (kidney) disease using twice-monthly administration for correction of untreated anemia 
and monthly and twice-monthly maintenance doses. The FDA has also issued a draft label (prescribing 
information), which we anticipate will be finalised (including an updated class label) based on the 
outcome of an FDA review of the use in kidney patients of currently marketed ESAs in the US: the agency\u8217?s 
Cardiovascular and Renal Drugs Advisory Committee is scheduled to meet in September. The FDA does not 
require further clinical studies with Mircera before approval. Also in May the EU authorities (CHMP) 
issued a positive opinion for Mircera for the treatment of anemia associated with chronic kidney disease 
using twice-monthly administration for correction of anemia and monthly maintenance doses.\line \line Roche 
is continuing the development of the product in the oncology setting. We are currently evaluating data 
from five phase I and II trials in patients with chemotherapy-induced anemia. These include a trial 
in patients with non-small cell lung cancer that was stopped in the second quarter of 2007 due to an 
imbalance in outcomes in the different treatment groups that does not appear to be related to the dosing 
of the study medications. Our development plans will also incorporate guidance from an FDA expert review 
in May of the use of existing ESAs in cancer patients and a similar EMEA review scheduled for July.\line \line Actemra 
(tocilizumab), an innovative IL-6 receptor inhibitor in development as a novel treatment for rheumatoid 
arthritis, passed another significant milestone with the announcement in June and July of positive results 
from the second and third of five international phase III studies. These data further confirm the critical 
role of interleukin 6 in the pathophysiology of RA. Results are expected later this year from the fourth 
of these trials. Roche plans to file marketing applications for the product in the US and EU towards 
the end of 2007.\line \line Ocrelizumab, a humanised anti-CD20 monoclonal antibody, 
is now in phase III development for moderate to severe rheumatoid arthritis. Ocrelizumab is also being 
investigated as a potential treatment for other autoimmune diseases, including systemic lupus erythematosus 
(SLE) and multiple sclerosis. Phase III studies in SLE are expected to begin later this year.\line \line Development 
of R1658, a cholesteryl ester transfer protein (CETP) inhibitor licensed from Japan Tobacco, remains 
on schedule. Roche is currently reviewing phase II data for the compound, which is being investigated 
as a potential therapy to reduce cardiovascular risk by raising levels of \u8216?good cholesterol\u8217?, or HDL. 
We expect to make a decision on development plans for R1658 later this year.\line \line {\b Acquisitions 
and partnering agreements \u8211? enabling access to new technologies} \line In the first half 
of 2007 Roche signed a licensing agreement with Toyama Chemical Co., Ltd for Toyama\u8217?s novel oral rheumatoid 
arthritis agent, T-5224, and entered a partnership with Transgene that gives Roche exclusive worldwide 
rights to compounds from Transgene\u8217?s therapeutic vaccine programme against human papillomavirus-mediated 
diseases. The acquisition in April of Therapeutic Human Polyclonals, Inc. further strengthens our capabilities 
in the development of enhanced monoclonal antibody therapeutics. In addition, in July we entered into 
a major alliance with Alnylam Pharmaceuticals, Inc., giving Roche access to Alnylam\u8217?s novel technology 
platform for developing RNA interference therapeutics.\line \line {\b Diagnostics 
Division\line } \line {\b Solid sales growth continues \u8211? strategic 
acquisitions for future growth} \line \line 
		Key figuresIn millions of CHF% change in CHF% change in local currenciesAs % of sales
	
		Sales4,55975100
	
		- Professional Diagnostics2,1108646
	
		- Diabetes Care1,5448634
	
		- Molecular Diagnostics574-3-213
	
		- Applied Science331997
	
		EBITDA1,3894330.5
	
		Operating profit9494320.8
	\line Roche 
Diagnostics\u8217? sales for the first six months of 2007 totalled 4.6 billion Swiss francs, an increase of 
5% in local currencies (7% in Swiss francs) over the same period in 2006. The division\u8217?s Professional 
Diagnostics, Diabetes Care and Applied Science businesses all posted solid single-digit sales increases. 
As expected, Roche Molecular Diagnostics continued to be affected by a decline in its industrial reagents 
segment.\line \line All regions except Japan contributed to growth, with sales advancing 
at double-digit rates in Latin America and Asia\u8211?Pacific, and European and North-American sales showing 
single-digit gains. As previously announced, the transactions to acquire 454 Life Sciences and BioVeris 
Corporation were completed in May and June, respectively.\line \line In June, Roche 
signed an acquisition agreement with NimbleGen Systems, Inc., a leading supplier of high-density microarrays, 
and commenced a tender offer to acquire Ventana Medical Systems, Inc. The acquisition of Ventana Medical 
Systems, if completed, will mark Roche\u8217?s entry into tissue-based diagnostics and be an important step 
in the Group\u8217?s strategy of delivering personalised healthcare solutions to patients.\line \line Divisional 
operating profit rose 3% to 949 million Swiss francs, while the operating profit margin declined 0.5 
percentage points to 20.8%. The margin decrease, which was in line with expectations, resulted from 
continued investments in launch activities and also higher costs of sales due to changes in the product 
mix and costs of instrument placements. EBITDA totalled 1.4 billion Swiss francs, or 30.5% of sales, 
compared with 31.2% in the first six months of 2006. This was well above the industry average.\line \line {\b Professional 
Diagnostics - Roche acquires BioVeris Corporation} \line Sales by Roche Professional Diagnostics 
(formerly Centralized Diagnostics and Near Patient Testing) rose 6%, fuelled by strong immunoassay sales. 
The immunochemistry business continued to grow twice as fast as the market, with interim sales advancing 
11%. Thyroid and cardiac assays were among the products driving growth. Sales of clinical chemistry 
products increased in line with market growth.\line In January Roche introduced the cobas 
e 411 immunoassay analyser, the first of the new cobas 4000 series of instruments for low-volume laboratories. 
It joins the cobas 6000 series of clinical chemistry and immunoassay analysers, launched last year for 
medium-volume laboratories.\line \line In June Roche acquired BioVeris Corporation 
for approximately 600 million US dollars, following clearance by the US authorities. This strengthens 
Roche Diagnostics\u8217? important and rapidly growing immunochemistry business by expanding it into new segments 
such as life science research, drug development and clinical trials. The global market for heterogeneous 
immunoassays, which is currently valued at 5.8 billion US dollars, is growing more than twice as fast 
as clinical chemistry. The transaction gives Roche ownership of the complete patent estate for the electrochemiluminescence 
(ECL) technology deployed in the Elecsys product line. \line \line Products for 
decentralised testing continue to contribute to the overall growth of this business area. The underlying 
growth of the coagulation self-monitoring business remains strong thanks to the CoaguChek platform. 
Sales of point-of-care cardiac assays accelerated further, particularly in Europe, following the February 
launch of the handheld cobas h 232 cardiovascular diagnostic system. Sales of blood gas systems rebounded 
in the first six months, helped by a strong focus on quality initiatives and successful major tenders 
in several countries. The strong upward trend in sales of hospital glucose testing products continued.\line \line {\b Diabetes 
Care - strong growth maintained} \line Roche Diabetes Care further strengthened its leading 
market position, with sales in the first half-year rising at a slightly above-market growth rate of 
6%. The Accu-Chek Aviva, Accu-Chek Go and Accu-Chek Compact blood glucose monitoring systems were the 
main growth drivers With our Accu-Chek Compact Plus and Accu-Chek Integra devices, we remain the leader 
in the market for integrated blood glucose monitoring systems. North American sales maintained momentum, 
advancing at a double-digit rate for the half-year. The Accu-Chek Spirit insulin pump, launched in the 
United States during the fourth quarter of 2006, has been well received in the US market and contributed 
to North American revenue growth. Sales grew strongly in Latin America and Asia\u8211?Pacific, where the Accu-Chek 
Spirit was launched in China and Korea. The global rollout of the new Accu-Chek Performa continued with 
launches in New Zealand and South Africa.\line \line {\b Molecular Diagnostics 
\u8211? automated HIV test launched in the United States } \line Roche Molecular Diagnostics 
maintained its market leadership despite the fact that revenues declined 2% due to a downturn in the 
industrial reagents segment. Excluding industrial sales, interim revenues rose 4%. Virology, the business 
area\u8217?s largest segment, grew by 6%, driven by continued placements of the automated Cobas AmpliPrep/Cobas 
TaqMan platform in Europe and Asia-Pacific. A new HIV test for this platform was approved by the FDA 
in May and was promptly launched in the key US market. A supply agreement for the test has already been 
signed with a major US lab customer. Sales in Molecular Diagnostics\u8217? second-largest segment, blood screening, 
remained flat.\line \line Sales in Europe and Asia-Pacific grew in line with the 
market. In Japan regulatory approval of automated Cobas AmpliPrep/Cobas TaqMan tests for HIV and the 
hepatitis B and C viruses (HBV, HCV) is expected to spur additional growth. The HBV and HCV tests were 
approved there in June, and the filing for the HIV test is now in the final stages of review. In the 
United States FDA reviews are under way of key tests for the virology segment (HBV, HCV), blood screening 
(West Nile virus and a multiplex assay for HIV, HBV and HCV) and women\u8217?s health (human papillomavirus). 
Development of microarray-based oncology tests for leukemia, lymphoma and mutations of the p53 tumour 
suppressor gene is progressing on schedule, as is work on companion diagnostics for oncology drugs such 
as our pertuzumab.\line \line {\b Applied Science \u8211? life science research 
products deliver strong growth} \line Roche Applied Science posted a strong, 9% sales 
increase, led by sales of the LightCycler 480, Genome Sequencer 20 and Genome Sequencer FLX systems 
and research reagents. The fast, innovative Genome Sequencer systems are establishing themselves in 
an expanding range of applications.\line \line The acquisition of 454 Life Sciences, 
completed in late May, has strengthened Roche\u8217?s position as a key player in the sequencing market. Roche 
and 454 Life Sciences collaborated under a joint research and marketing agreement prior to the acquisition. 
The proposed acquisition of NimbleGen Systems, Inc., announced in June, will take Roche\u8217?s strategy of 
reinforcing its position as a complete solution provider in genomics research another step forward, 
by expanding activities into the microarray segment. This new segment will complement Roche Diagnostics\u8217? 
existing portfolio of genomic research tools. Subject to regulatory clearance, the transaction is expected 
to close in the third quarter of this year.\line \line \line {\b About 
Roche } \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As one of the world\u8217?s 
biggest biotech companies and an innovator of products and services for the early detection, prevention, 
diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people\u8217?s 
health and quality of life. Roche is one of the world leaders in in-vitro diagnostics and drugs for 
cancer and transplantation, a market leader in virology and active in other major therapeutic areas 
such as autoimmune diseases, inflammation, metabolism and central nervous system. In 2006 sales by the 
Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted sales 
of 8.7 billion Swiss francs. Roche employs roughly 75,000 people worldwide and has R&D agreements 
and strategic alliances with numerous partners, including majority ownership interests in Genentech 
and Chugai. Additional information about the Roche Group is available on the Internet at www.roche.com.\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All 
trademarks used or mentioned in this release are protected by law.\line \par}\line Annex (http://www.roche.com/mrhy07ane.pdf)\line \line {\b Additional 
information} \line - Media release including a full set of tables\line - 
Half-Year Report 2007\line - Presentation (http://www.roche.com/irphy07.pdf) (Investor 
Relations)\line - Roche Pharma Pipeline\line - Date of publication 
of the nine months sales release 2007: 18 October (tentative)\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 {\i {\b Disclaimer: 
Cautionary statement regarding forward-looking statements} \line This document contains 
certain forward-looking statements. These forward-looking statements may be identified by words such 
as \u8216?believes\u8217?, \u8216?expects\u8217?, \u8216?anticipates\u8217?, \u8216?projects\u8217?, \u8216?intends\u8217?, \u8216?should\u8217?, \u8216?seeks\u8217?, \u8216?estimates\u8217?, \u8216?future\u8217? 
or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. 
Various factors may cause actual results to differ materially in the future from those reflected in 
forward-looking statements contained in this document, among others: (1) pricing and product initiatives 
of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability 
in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange 
rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing 
of new products or new uses of existing products, including without limitation negative results of clinical 
trials or research projects, unexpected side-effects of pipeline or marketed products; (6) increased 
government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate 
protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; 
and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not 
a profit forecast and should not be interpreted to mean that Roche\u8217?s earnings or earnings per share 
for 2006 or any subsequent period will necessarily match or exceed the historical published earnings 
or earnings per share of Roche.} \line \par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}